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ROCK-2 activation induces malignant conversion in rasHa-mediated transgenic mouse skin 
carcinogenesis via p53 loss, elevated NFκβ and tenascin C-associated rigidity; but p21 inhibits 
early-stage progression. 
 
To study mechanisms of tumour progression, transgenic mice that expressed a 4-hydroxytamoxifen 
(4HT)-activated human ROCK 2-estrogen receptor fusion transgene from a keratin 14 promoter 
[K14.ROCKer] were crossed to mice expressing activated rasHa exclusively in epidermal transit 
amplifying keratinocytes [HK1.ras1205]. 4HT-treatments of K14.ROCKer mice [3/wk; 26 wks] induced 
epidermal and follicular hyperplasia but no papillomas; whilst untreated K14.ROCKer-HK1.ras1205 
cohorts exhibited papillomas similar to HK1.ras1205 controls [16wks]. In contrast by 8 weeks, 4HT-
treated  K14.ROCKer-HK1.ras1205 histotypes comprised a mixed papilloma/well-differentiated 
squamous cell carcinoma [wdSCC] that exhibited p53 loss, beginning in papilloma basal layers 
leading to increased proliferation. In addition papilloma histotypes also exhibited novel, ROCKer-
associated NF-κβ expression in basal layer keratinocytes, prior to malignant conversion. By 12 weeks, 
K14.ROCKer-HK1.ras1205 wdSCCs exhibited further increases in NF-κβ expression together with the 
appearance of tenascin C expression, an extracellular matrix molecule indicative of elevated rigidity; 
yet despite continued ROCK2 activities, progression to SCC required loss of compensatory p21 
expression. K14.ROCKer-HK1.ras1205 papillomatogenesis also required a wound-promotion stimulus, 
confirmed by breeding K14.ROCKer into promotion-insensitive HK1.ras1276 mice, suggesting a 
permissive K14.ROCKer-HK1.ras1205 papilloma context [wound-promoted/NF-κβ+ve/p53-ve/p21+ve] 
preceded K14.ROCKer-mediated] malignant conversion [p-Mypt1/ actinomyosin-mediated mechano-
transduction-tenascin C/rigidity]. Malignancy depended on ROCKer expression, as cessation of 4HT-
treatment induced a p21-associated differentiation in wdSCC and appearance of  novel papilloma 
outgrowths expressing intense, basal-layer p21 which confined endogenous ROCK2/p-Mypt1/NF-κβ 
to supra-basal layers, and restored basal-layer p53. In later SCCs, 4HT-cessation became irrelevant as 
endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-κβ and 
tenascin C-associated rigidity, with p-Mypt1/actinomyosin-mediated contractility to facilitate 
invasion. Thus, ROCK2 activation induces malignancy in rasHa-initiated/promoted papillomas in the 
context of p53 loss, increased proliferation, and novel NF-κβ expression; whilst increased rigidity was 
associated with conversion and progression. However, p21 inhibition of early-stage malignant 
progression and intense expression in papilloma outgrowths identifies a significant antagonism 
between p21 and rasHa/ROCK2/NF-κβ signalling in skin carcinogenesis.  
 
